* previous use of nintedanib or pirfenidone * administration of fluvoxamine 7 days prior to admission to icu * severe hepatic impairment (liver enzymes and bilirubin\>2 of normal upper limit, at day 0) or end stage liver disease * severe renal impairment (crcl \<30 ml/min) or end stage renal disease requiring dialysis * pregnancy * participation in any other clinical trial 30 days prior to enrollment

* previous use of nintedanib or pirfenidone * administration of fluvoxamine 7 days prior to admission to icu * severe hepatic impairment (liver enzymes and bilirubin\>2 of normal upper limit, at day 0) or end stage liver disease * severe renal impairment (crcl \<30 ml/min) or end stage renal disease requiring dialysis * pregnancy * participation in any other clinical trial 30 days prior to enrollment

- previous use of nintedanib or pirfenidone - administration of fluvoxamine 7 days prior to admission to icu - severe hepatic impairment (liver enzymes and bilirubin>2 of normal upper limit, at day 0) or end stage liver disease - severe renal impairment (crcl <30 ml/min) or end stage renal disease requiring dialysis - pregnancy - participation in any other clinical trial 30 days prior to enrollment

- previous use of nintedanib or pirfenidone - administration of fluvoxamine 7 days prior to admission to icu - severe hepatic impairment (liver enzymes and bilirubin>2 of normal upper limit, at day 0) or end stage liver disease - severe renal impairment (crcl <30 ml/min) or end stage renal disease requiring dialysis - pregnancy - participation in any other clinical trial 30 days prior to enrollment